Aimmune Therapeutics, Inc. (AIMT)
|Net Income (ttm)||-287.03M|
|Trading Day||Oct 13, 2020|
|Day's Range||34.48 - 34.56|
|52-Week Range||10.09 - 37.00|
Vevey, October 14, 2020
Aimmune Therapeutics Inc shareholders have backed Nestle's $2 billion offer to gain full ownership of the first U.S.-approved peanut allergy treatment, which has struggled with a slow launch d...
Nestlé announces results of tender offer for Aimmune Therapeutics, Inc.
Nestle picked my Best Stocks pick up for a steal, but I believe the decade of biotechnology is just now getting started. The post Best Stocks for 2020: Aimmune Therapeutics Gets Picked Up for ...
AIMT's stock fell precipitously amid the COVID-19 pandemic, despite receiving FDA approval for its Palforzia treatment (the first FDA approved treatment for peanut allergies).
SHAREHOLDER ALERT: Monteverde & Associates PC Announces an Investigation of Aimmune Therapeutics, Inc. - AIMT
NEW YORK, Sept. 18, 2020 /PRNewswire/ -- Juan Monteverde, founder and managing partner at Monteverde & Associates PC, a national securities firm headquartered at the Empire State Building in N...
Vevey, September 14, 2020
NEW YORK, Sept. 10, 2020 /PRNewswire/ -- Aimmune Therapeutics, Inc.
Nestle is buying the small-cap biotech, and it's paying a high premium.
Kaskela Law LLC Announces Stockholder Investigation of Aimmune Therapeutics, Inc. (AIMT) and Encourages Investors to Contact the Firm
PHILADELPHIA, Sept. 5, 2020 /PRNewswire/ -- Kaskela Law LLC announces that it is investigating Aimmune Therapeutics, Inc.
These drugmakers are in the sweet spot to provide market-beating returns.
AIMMUNE INVESTOR ALERT By the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Aimmune Therapeutics Inc. - AIMT
NEW ORLEANS--(BUSINESS WIRE)--Former Attorney General of Louisiana Charles C. Foti, Jr., Esq.
Nestle CEO on the company's Aimmune Therapeutics acquisition
Mark Schneider, Nestle CEO, joins 'Closing Bell' to discuss the company's acquisition of peanut allergy treatment maker Aimmune and on consumer trends he's seeing.
Wilmington, Delaware--(Newsfile Corp. - September 1, 2020) - Rigrodsky & Long, P.A.
Aimmune (AIMT) reaches an agreement with Nestle, S.A wherein the latter will acquire the company in an all-cash transaction worth $2.6 billion. Shares surge.
Swiss giant adds third drug to its portfolio this year
Aimmune Therapeutics confirms $2B Nestle acquisition
On Monday, Aimmune Therapeutics announced that it had agreed to Nestle’s $2 billion dollar acquisition.
NEW YORK, Aug. 31, 2020 /PRNewswire/ -- WeissLaw LLP is investigating possible breaches of fiduciary duty and other violations of law by the board of directors of Aimmune Therapeutics, Inc. ("...
It was a mixed day for the markets.
Aimmune Therapeutics' news of its agreement with Nestle regarding its food allergy treatment has AIMT stock soaring way higher on Monday.
Aimmune Therapeutics Inc. (NASDAQ: AIMT) shares more than doubled to start out the week after reports surfaced that the company would be acquired by Nestle Health Sciences, a subsidiary of the...
Nestlé is buying the maker of a peanut allergy drug for children for $2.6 billion as it deepens its focus into health care and nutrition.
NEW YORK--(BUSINESS WIRE)--Rowley Law PLLC is investigating potential securities law violations by Aimmune Therapeutics, Inc. (NASDAQ: AIMT) and its board of directors concerning the proposed ...
Nestlé is shelling out an estimated $2.6 billion to buy a biopharmaceutical company best known for its peanut-allergy treatment. Nestlé is shelling out an estimated $2.6 billion to buy a biop...
SHAREHOLDER ALERT: Levi & Korsinsky, LLP Notifies Investors of an Investigation into the Fairness of the Sale of Aimmune Therapeutics, Inc. to Nestlé S.A.
New York, New York--(Newsfile Corp. - August 31, 2020) - The following statement is being issued by Levi & Korsinsky, LLP:To view an enhanced version of this graphic, please visit:https://orde...
Swiss food giant Nestle early Monday announced an agreement to buy Aimmune Therapeutics, the maker of the only approved drug to treat peanut allergies, for $2.6 billion. AIMT stock soared.
Nestle is gobbling up the peanut allergy drugmaker Aimmune Therapeutics for a cool $2.6 billion.
The world’s largest consumer products company, Nestlé S.A., has agreed to acquire Aimmune Therapeutics Inc.
Oak Stone Limited Comments On Nestle As They Agree To Acquire Allergy Treatment Maker Aimmune For $2.6 Billion
TAIPEI, Taiwan--(BUSINESS WIRE)--Oak Stone Limited have commented on Nestle after it announced its definitive agreement to purchase biopharma company Aimmune for $2.6 billion.
Nestle (SWX: NESN) on Monday expressed plans of buying Aimmune Therapeutics for £1.95 billion. The Brisbane-based biopharmaceutical company is largely known for its peanut allergy treatment.
(AIMT) Alert: Johnson Fistel Investigates Proposed Sale of Aimmune Therapeutics; Is $34.50 a Fair Price?
SAN DIEGO, Aug. 31, 2020 /PRNewswire/ -- Shareholder rights law firm Johnson Fistel, LLP has launched an investigation into whether the board members of Aimmune Therapeutics, Inc.
Food allergies an immense opportunity, Nestle Health Science chief says
Nestlé Health Science CEO Greg Behar discusses the company's acquisition of food allergy biopharma company Aimmune Therapeutics and the opportunity in the food allergy space.
Nestle plans to pay $2 billion to gain full ownership of peanut allergy treatment maker Aimmune Therapeutics, as the Swiss company expands its fast-growing health science business.
Nestle S.A. (OTC: NSRGY) subsidiary Nestle Health Sciences (NHSc) is aquiring biopharma company Aimmune Therapeutics, Inc.
Nestle said on Thursday it was offering $34.50 per share for the remaining 74.4% in peanut allergy treatment maker Aimmune Therapeutics it does not already own, adding a potential blockbuster ...
Aimmune Therapeutics Enters Definitive Agreement with Sociétés des Produits Nestlé S.A., Part of Nestlé Health Science
BRISBANE, Calif.--(BUSINESS WIRE)--Aimmune Therapeutics Inc.
This press release is also available in Français (pdf) and Deutsch (pdf)
Thanks to bad news for its competitor, this company behind the first FDA-approved peanut allergy treatment could be ripe for a rebound.
BRISBANE, Calif.--(BUSINESS WIRE)--Aimmune Therapeutics to Present at the 2020 Wedbush PacGrow Healthcare Virtual Conference
Is this battered biotech stock now a good deal for investors?
Aimmune Therapeutics Inc (NASDAQ: AIMT) shares, which recovered Monday following an earnings-induced sell-off Friday, are adding to the gains.
Aimmune Therapeutics, Inc. (AIMT) CEO Jayson Dallas on Q2 2020 Results - Earnings Call Transcript
Aimmune Therapeutics (AIMT) delivered earnings and revenue surprises of 0.00% and -100.00%, respectively, for the quarter ended June 2020. Do the numbers hold clues to what lies ahead for the ...
Aimmune Therapeutics Announces Second Quarter 2020 Financial Results and Provides Recent Operational Highlights
BRISBANE, Calif.--(BUSINESS WIRE)--Aimmune Therapeutics Announces Second Quarter 2020 Financial Results and Provides Recent Operational Highlights
Aimmune Therapeutics to Host Conference Call and Webcast to Discuss Second Quarter 2020 Financial Results and Recent Operational Highlights
BRISBANE, Calif.--(BUSINESS WIRE)--Aimmune Therapeutics to Host Conference Call and Webcast to Discuss Second Quarter 2020 Financial Results and Recent Operational Highlights
Full Results of Aimmune’s Pivotal Phase 3 European ARTEMIS Trial of PALFORZIA® Published in The Lancet Child & Adolescent Health
BRISBANE, Calif.--(BUSINESS WIRE)--Full Results of Aimmune’s Pivotal Phase 3 European ARTEMIS Trial of PALFORZIA® Published in The Lancet Child & Adolescent Health
These under-the-radar names pack some huge growth potential.
Aimmune Therapeutics may be struggling now in the Best Stocks contest, but the future is still bright for AIMT stock thanks to Palforzia. The post Best Stocks for 2020: Expect Aimmune Stock to...
Armed with the recent approval of Palforzia, the first FDA-approved treatment for peanut allergy, could Aimmune Therapeutics turn things around?
Aimmune Shares Look Cheap On A Discounted Cash Flow Basis
Aimmune Therapeutics, a clinical-stage biopharmaceutical company, develops and commercializes product candidates for the treatment of peanut and other food allergies. Its lead Characterized Oral Desensitization ImmunoTherapy (CODIT) product candidate is AR101, an investigational biologic, which is in Phase III clinical trial for the treatment of patients with peanut allergy. The company also engages in the research and development of AR201, a CODIT product candidate for the treatment of egg allergy in pediatric and young adult patients; and oth... [Read more...]
|IPO Date |
Aug 6, 2015
Jayson Donald Alexander Dallas
|Stock Exchange |
|Ticker Symbol |